3D-Printed Phenylboronic Acid-Bearing Hydrogels for Glucose-Triggered Drug Release
Jérémy Odent,
Nicolas Baleine,
Serena Maria Torcasio,
Sarah Gautier,
Olivier Coulembier,
Jean-Marie Raquez
Affiliations
Jérémy Odent
Laboratory of Polymeric and Composite Materials (LPCM), Center of Innovation and Research in Materials and Polymers (CIRMAP), University of Mons (UMONS), Place du Parc 20, 7000 Mons, Belgium
Nicolas Baleine
Laboratory of Polymeric and Composite Materials (LPCM), Center of Innovation and Research in Materials and Polymers (CIRMAP), University of Mons (UMONS), Place du Parc 20, 7000 Mons, Belgium
Serena Maria Torcasio
Laboratory of Polymeric and Composite Materials (LPCM), Center of Innovation and Research in Materials and Polymers (CIRMAP), University of Mons (UMONS), Place du Parc 20, 7000 Mons, Belgium
Sarah Gautier
Laboratory of Polymeric and Composite Materials (LPCM), Center of Innovation and Research in Materials and Polymers (CIRMAP), University of Mons (UMONS), Place du Parc 20, 7000 Mons, Belgium
Olivier Coulembier
Laboratory of Polymeric and Composite Materials (LPCM), Center of Innovation and Research in Materials and Polymers (CIRMAP), University of Mons (UMONS), Place du Parc 20, 7000 Mons, Belgium
Jean-Marie Raquez
Laboratory of Polymeric and Composite Materials (LPCM), Center of Innovation and Research in Materials and Polymers (CIRMAP), University of Mons (UMONS), Place du Parc 20, 7000 Mons, Belgium
Diabetes is a major health concern that the next-generation of on-demand insulin releasing implants may overcome via personalized therapy. Therein, 3D-printed phenylboronic acid-containing implants with on-demand glucose-triggered drug release abilities are produced using high resolution stereolithography technology. To that end, the methacrylation of phenylboronic acid is targeted following a two-step reaction. The resulting photocurable phenylboronic acid derivative is accordingly incorporated within bioinert polyhydroxyethyl methacrylate-based hydrogels at varying loadings. The end result is a sub-centimeter scaled 3D-printed bioinert implant that can be remotely activated with 1,2-diols and 1,3-diols such as glucose for on-demand drug administration such as insulin. As a proof of concept, varying glucose concentration from hypoglycemic to hyperglycemic levels readily allow the release of pinacol, i.e., a 1,2-diol-containing model molecule, at respectively low and high rates. In addition, the results demonstrated that adjusting the geometry and size of the 3D-printed part is a simple and suitable method for tailoring the release behavior and dosage.